Multaq and Blindness - a phase IV clinical study of FDA data

Summary:

Blindness is reported as a side effect among people who take Multaq (dronedarone hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Synthroid, and have Diabetes.

The phase IV clinical study analyzes which people have Blindness when taking Multaq. It is created by eHealthMe based on reports of 10,572 people who have side effects when taking Multaq from the FDA, and is updated regularly.

What is Multaq?

Multaq has active ingredients of dronedarone hydrochloride. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 11,053 Multaq users. Check the latest studies of Multaq.

What is Blindness?

Blindness is found to be associated with 1,509 drugs and 1,987 conditions by eHealthMe. Check the latest studies of Blindness.

On Jul, 19, 2026

10,572 people reported to have side effects when taking Multaq.
Among them, 24 people (0.23%) have Blindness.

Among these 24 people:

How long have people been on Multaq when they have Blindness? *

What is the gender of people who have Blindness when taking Multaq? *

female: 62.5 %
male: 37.5 %

What is the age of people who have Blindness when taking Multaq? *

What are other drugs people take besides Multaq? *

What are other side effects people have besides Blindness? *

Vision Blurred: 9 people, 37.50%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 4 people, 16.67%
Dyspnea (difficult or laboured breathing): 4 people, 16.67%
Constipation: 4 people, 16.67%
Halo Vision (rainbow vision): 3 people, 12.50%
Fatigue (feeling of tiredness): 3 people, 12.50%
Memory Loss: 3 people, 12.50%
Chest Pain: 3 people, 12.50%
Rashes (redness): 2 people, 8.33%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 8.33%

What are the existing conditions these people have? *

Diabetes: 3 people, 12.50%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 8.33%
Retinal Haemorrhage (bleeding from retina): 2 people, 8.33%
Lung Cancer - Small Cell (lung cancer): 2 people, 8.33%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 8.33%
High Blood Pressure: 2 people, 8.33%
Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 1 person, 4.17%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 1 person, 4.17%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 4.17%
Cutaneous Lupus Erythematosus (own immune system attacks various cells causing a wide variety of signs and symptoms): 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Multaq and have Blindness?

- Check whether Blindness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Multaq:

Multaq (11,053 reports)

Blindness treatments and more:

Blindness (45,948 reports)

Browse all side effects of Multaq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Blindness:

Blindness (1,509 drugs)

Browse all the conditions that are associated with Blindness:

Blindness (1,987 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dronedarone hydrochloride (the active ingredients of Multaq) and Multaq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.